AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Altimmune, Inc. Director's Dealing 2010

Dec 16, 2010

33207_dirs_2010-12-15_71788d59-f270-4950-abb3-f285f31a2c48.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: PHARMATHENE, INC (PIP)
CIK: 0001326190
Period of Report: 2010-12-13

Reporting Person: Riddle Valerie D (SVP, Medical Director)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2010-12-13	Stock Options (right to buy)	$3.60	A	37500	Acquired	2020-12-13	Common Stock (37500)	Direct

Footnotes

F1: The options vest as follows: 25% vest on each of June 1, 2012, June 1, 2013, June 1, 2014 and June 1, 2015.

F2: On December 13, 2010, the date such options were granted, the closing price of the Issuer's Common Stock on the NYSE Amex was
$3.60 per share.